New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
Unlocking the next generation of life sciences innovations will depend on researchers' abilities to not just uncover new data, but to identify patterns at ...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Perpetual Medicines announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for pe...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, O...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
© 2025 Biopharma Boardroom. All Rights Reserved.
